Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Rezolute, Inc. RZLT
$2.07
+$0.04 (1.98%)
На 18:03, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
72918648.00000000
-
week52high
3.87
-
week52low
1.34
-
Revenue
0
-
P/E TTM
-3
-
Beta
2.16297500
-
EPS
-1.12000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 10:59
Описание компании
Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Cantor Fitzgerald | Overweight | 15 июн 2022 г. | |
| Canaccord Genuity | Buy | Buy | 29 ноя 2021 г. |
| JMP Securities | Market Outperform | Market Outperform | 15 ноя 2021 г. |
| Roth Capital | Buy | 08 сент 2021 г. | |
| Oppenheimer | Outperform | 27 мая 2021 г. | |
| Cantor Fitzgerald | Overweight | 13 сент 2022 г. | |
| Jefferies | Buy | 12 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Kim Young-Jin | A | 40000 | 40000 | 23 июн 2022 г. |
| FAUCHET PHILIPPE | A | 80000 | 80000 | 23 июн 2022 г. |
| ROBERTS BRIAN KENNETH | A | 700000 | 700000 | 23 июн 2022 г. |
| Hogenhuis Wladimir | A | 80000 | 80000 | 23 июн 2022 г. |
| Elam Nevan C | A | 2600000 | 2600000 | 23 июн 2022 г. |
| Labrucherie Gil M | A | 80000 | 80000 | 23 июн 2022 г. |
| KREHER NERISSA | A | 80000 | 80000 | 23 июн 2022 г. |
| ROBERTS BRIAN KENNETH | A | 22552 | 300 | 19 мая 2022 г. |
| ROBERTS BRIAN KENNETH | A | 22252 | 200 | 18 мая 2022 г. |
| ROBERTS BRIAN KENNETH | A | 22052 | 1000 | 17 мая 2022 г. |
Новостная лента
Rezolute to Present at the Jefferies London Healthcare Conference
GlobeNewsWire
01 ноя 2022 г. в 07:00
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to shift the treatment paradigms of devastating metabolic diseases, today announced that Nevan Charles Elam, Chief Executive Officer and Founder, will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 17, 2022, at 11:25 a.m. EST/4:25 p.m. GMT.
Rezolute, Inc. (RZLT) Upgraded to Buy: Here's Why
Zacks Investment Research
21 сент 2022 г. в 13:33
Rezolute, Inc. (RZLT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Rezolute (RZLT) Posts Positive Data From Congenital HI Study
Zacks Investment Research
24 мар 2022 г. в 15:03
Rezolute (RZLT) releases favorable data from the phase IIb RIZE study on its lead candidate RZ358, currently being investigated for congenital hyperinsulinism.
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
GlobeNewsWire
13 окт 2021 г. в 08:10
REDWOOD CITY, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced the pricing of an underwritten public offering of 6,030,847 shares of its common stock at a public offering price of $6.50 per share and of pre-funded warrants to purchase 1,661,461 shares of its common stock at a public offering price of $6.49 per pre-funded warrant, which represents the per share public offering price for the common stock less the $0.01 per share exercise price for each pre-funded warrant.
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
GlobeNewsWire
12 окт 2021 г. в 16:05
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a clinical-stage biopharmaceutical company developing transformative therapies for metabolic diseases associated with chronic glucose imbalance, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering, and, in lieu of common stock, Rezolute intends to offer and sell to certain investors pre-funded warrants to purchase shares of its common stock. Concurrently with the public offering and by means of a prospectus supplement and accompanying prospectus, Rezolute is offering to sell shares of its common stock directly to certain institutional investors that are current shareholders, in a registered direct offering.